Transforming Therapeutic Approaches with PROTAC Technology: New Targets and Potentials

Abstract

This Patent Highlight delves into the ground-breaking impact of Proteolysis Targeting Chimeras (PROTACs) on targeted protein degradation, offering novel strategies to eliminate pathogenic proteins. By exploring the cutting-edge development of compounds targeting IRAK-4 and CDK2, this work illuminates PROTACs' role in treating immune disorders and cancer. The analysis not only highlights the specificity and potential of PROTACs in transforming disease treatment but also addresses the challenges and future directions of this technology, emphasizing its broad applicability and the promise of more effective therapeutic strategies.

Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions

“…These compounds specifically target androgen receptors for prostate cancer treatment and the estrogen receptor for breast cancer. Currently, they are undergoing phase II and III clinical trials, respectively (FDA clinical trial number NCT05909397) …”